• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

GATA3 免疫组织化学在鉴别尿路上皮癌与前列腺腺癌,以及宫颈、肛门和肺的鳞状细胞癌中的应用。

Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung.

机构信息

Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21231, USA.

出版信息

Am J Surg Pathol. 2012 Oct;36(10):1472-6. doi: 10.1097/PAS.0b013e318260cde7.

DOI:10.1097/PAS.0b013e318260cde7
PMID:22982890
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3444740/
Abstract

Distinguishing invasive high-grade urothelial carcinoma (UC) from other carcinomas occurring in the genitourinary tract may be difficult. The differential diagnosis includes high-grade prostatic adenocarcinoma, spread from an anal squamous cell carcinoma (SCC), or spread from a uterine cervical SCC. In terms of metastatic UC, the most common problem is differentiating spread of UC to the lung from a primary pulmonary SCC. Immunohistochemical analysis (IHC) for GATA binding protein 3 (GATA3), thrombomodulin (THROMBO), and uroplakin III was performed on a tissue microarray (TMA) containing 35 cases of invasive high-grade UC. GATA3 IHC was also performed on TMAs containing 38 high-grade (Gleason score ≥8) prostatic adenocarcinomas, representative tissue sections from 15 invasive anal SCCs, representative tissue sections from 19 invasive cervical SCCs, and TMAs with 12 invasive cervical carcinomas of the cervix [SCC (n=10), SCC with neuroendocrine features (n=1), and adenosquamous carcinoma (n=1)]. In addition, GATA3 IHC was performed on representative tissue sections from 15 pulmonary UC metastases and a TMA with 25 SCCs of the lung and 5 pulmonary non-small cell carcinomas with squamous features. GATA3, THROMBO, and uroplakin III were positive in 28 (80%), 22 (63%), and 21 (60%) cases of high-grade UC, respectively. All cases of GATA3-positive staining were nonfocal; 25 (89%) cases demonstrated moderate to strong staining, and 3 (11%) demonstrated weak staining. Of the 7 cases that failed to express GATA3, 5 were positive for THROMBO and/or uroplakin III, whereas 2 were negative for all 3 markers. None of the 38 high-grade prostatic adenocarcinomas was positive for GATA3. Weak GATA3 staining was present in occasional basal cells of benign prostate glands, in a few benign atrophic glands, and in urothelial metaplasia. Of the 15 cases of anal SCCs, 2 (7%) cases showed focal weak staining, and 1 (3%) showed focal moderate staining. Weak staining was also rarely observed in the benign anal squamous epithelium. Of the 31 uterine cervical carcinomas, 6 (19%) showed weak GATA3 staining (3 nonfocal and 3 focal), and 2 (6%) demonstrated focal moderate staining. Twelve (80%) of the metastatic UCs to the lung were positive for GATA3, with 11 cases showing diffuse moderate or strong staining and 1 case showing focal moderate staining. None of the pulmonary SCCs or non-small cell carcinomas with squamous features was GATA3 positive. GATA3 IHC is a sensitive marker for UC, and positive staining in UC is typically nonfocal and moderate or strong in intensity. GATA3 is also highly specific in excluding high-grade prostate adenocarcinoma. Although some cervical and anal SCCs can be GATA3 positive, unlike in UC, staining is more commonly focal and weak. GATA3 is also a useful maker when diagnosing metastatic UC to the lung.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aafa/3444740/70b7ee301d4a/nihms388559f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aafa/3444740/70b7ee301d4a/nihms388559f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aafa/3444740/70b7ee301d4a/nihms388559f1.jpg
摘要

鉴别泌尿生殖道侵袭性高级别尿路上皮癌(UC)与其他发生在泌尿生殖道的癌可能具有挑战性。鉴别诊断包括高级别前列腺腺癌、来自肛门鳞状细胞癌(SCC)的转移或来自子宫颈 SCC 的转移。就转移性 UC 而言,最常见的问题是区分 UC 向肺部的转移与原发性肺部 SCC。对包含 35 例侵袭性高级别 UC 的组织微阵列(TMA)进行 GATA 结合蛋白 3(GATA3)、血栓调节蛋白(THROMBO)和尿路上皮蛋白 III(uroplakin III)的免疫组织化学分析(IHC)。还对包含 38 例高级别(Gleason 评分≥8)前列腺腺癌、15 例侵袭性肛门 SCC 的代表性组织切片、19 例侵袭性子宫颈 SCC 的代表性组织切片以及包含 12 例子宫颈浸润性 SCC(SCC[n=10]、具有神经内分泌特征的 SCC[n=1]和腺鳞癌[n=1])的 TMA 进行了 GATA3 IHC。此外,对 15 例肺部 UC 转移的代表性组织切片和包含 25 例肺部 SCC 和 5 例具有鳞状特征的肺部非小细胞癌的 TMA 进行了 GATA3 IHC。GATA3、THROMBO 和 uroplakin III 在 28(80%)、22(63%)和 21(60%)例高级别 UC 中分别呈阳性。所有 GATA3 阳性染色的病例均为非局灶性;25(89%)例表现为中度至强染色,3(11%)例表现为弱染色。在未能表达 GATA3 的 7 例病例中,5 例对 THROMBO 和/或 uroplakin III 呈阳性,而 2 例对所有 3 种标志物均呈阴性。38 例高级别前列腺腺癌均无 GATA3 阳性。良性前列腺腺体的偶尔基底细胞、少数良性萎缩腺体和尿路上皮化生中存在弱阳性 GATA3 染色。在 15 例肛门 SCC 中,2(7%)例病例出现局灶性弱阳性染色,1(3%)例病例出现局灶性中度染色。良性肛门鳞状上皮中也很少观察到弱阳性染色。在 31 例子宫颈 SCC 中,6(19%)例显示弱阳性 GATA3 染色(3 例非局灶性和 3 例局灶性),2(6%)例显示局灶性中度染色。12(80%)例肺部 UC 转移灶 GATA3 阳性,11 例弥漫性中度或强染色,1 例局灶性中度染色。无肺部 SCC 或具有鳞状特征的非小细胞癌为 GATA3 阳性。GATA3 IHC 是 UC 的敏感标志物,UC 中的阳性染色通常为非局灶性和中度或强强度。GATA3 在排除高级别前列腺腺癌方面也具有高度特异性。虽然一些宫颈和肛门 SCC 可以是 GATA3 阳性,但与 UC 不同,染色通常更常见于局灶性和弱阳性。GATA3 也是诊断肺部转移性 UC 的有用标志物。

相似文献

1
Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung.GATA3 免疫组织化学在鉴别尿路上皮癌与前列腺腺癌,以及宫颈、肛门和肺的鳞状细胞癌中的应用。
Am J Surg Pathol. 2012 Oct;36(10):1472-6. doi: 10.1097/PAS.0b013e318260cde7.
2
GATA3 immunohistochemical expression in invasive urothelial carcinoma.GATA3在浸润性尿路上皮癌中的免疫组化表达
Urol Oncol. 2016 Oct;34(10):432.e9-432.e13. doi: 10.1016/j.urolonc.2016.04.016. Epub 2016 May 27.
3
Is GATA3 expression maintained in regional metastases?: a study of paired primary and metastatic urothelial carcinomas.GATA3 表达是否在局部转移中维持?:配对原发性和转移性尿路上皮癌的研究。
Am J Surg Pathol. 2013 Dec;37(12):1876-81. doi: 10.1097/PAS.0b013e31829e2525.
4
GATA3 expression in metastatic urothelial carcinoma in fine needle aspiration cell blocks: a review of 25 cases.细针穿刺细胞块中GATA3在转移性尿路上皮癌中的表达:25例病例回顾
Diagn Cytopathol. 2014 Sep;42(9):809-15. doi: 10.1002/dc.23131. Epub 2014 Feb 28.
5
Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.前列腺中免疫组织化学应用的最佳实践建议:国际泌尿病理学会共识会议报告。
Am J Surg Pathol. 2014 Aug;38(8):e6-e19. doi: 10.1097/PAS.0000000000000238.
6
Utility of uroplakin II expression as a marker of urothelial carcinoma.尿路上皮蛋白II表达作为尿路上皮癌标志物的效用。
Hum Pathol. 2015 Jan;46(1):58-64. doi: 10.1016/j.humpath.2014.09.007. Epub 2014 Oct 2.
7
Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung.选择免疫组织化学标志物以区分转移性高级尿路上皮癌和原发性低分化浸润性肺鳞状细胞癌。
Arch Pathol Lab Med. 2012 Nov;136(11):1339-46. doi: 10.5858/arpa.2011-0575-OA.
8
Usefulness of GATA3 and p40 immunostains in the diagnosis of metastatic urothelial carcinoma in cytology specimens.GATA3 和 p40 免疫染色在细胞学标本中诊断转移性尿路上皮癌的作用。
Cancer Cytopathol. 2014 Jun;122(6):468-73. doi: 10.1002/cncy.21424. Epub 2014 Apr 7.
9
Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.胎盘S100(S100P)和GATA3:通过互补DNA微阵列发现的移行上皮和尿路上皮癌标志物。
Am J Surg Pathol. 2007 May;31(5):673-80. doi: 10.1097/01.pas.0000213438.01278.5f.
10
A comprehensive analysis of GATA3 expression in carcinomas of various origins with emphasis on lung carcinomas.全面分析 GATA3 在不同来源的癌中的表达情况,重点是肺癌。
Monaldi Arch Chest Dis. 2023 Aug 29;94(2). doi: 10.4081/monaldi.2023.2641.

引用本文的文献

1
Integrative Analysis of Expression and Variants as Prognostic Biomarkers in Urothelial Cancer.尿路上皮癌中作为预后生物标志物的表达与变异的综合分析
Int J Mol Sci. 2025 Jul 2;26(13):6378. doi: 10.3390/ijms26136378.
2
Expression of Gata Binding Protein 3 as a Prognostic Factor in Urogenital Lesions and Its Association With Morphology.Gata结合蛋白3在泌尿生殖系统病变中作为预后因素的表达及其与形态学的关系。
Cureus. 2023 Nov 29;15(11):e49635. doi: 10.7759/cureus.49635. eCollection 2023 Nov.
3
TRPS1 expression in primary and metastatic prostatic adenocarcinoma, muscle invasive bladder urothelial carcinoma, and breast carcinoma: Is TRPS1 truly specific and sensitive for a breast primary?

本文引用的文献

1
GATA Transcription Factors and Cancer.GATA转录因子与癌症
Genes Cancer. 2010 Dec;1(12):1178-88. doi: 10.1177/1947601911404223.
2
Different immunohistochemical and ultrastructural phenotypes of squamous differentiation in bladder cancer.膀胱癌中鳞状分化的不同免疫组化和超微结构表型。
Virchows Arch. 2011 Mar;458(3):301-12. doi: 10.1007/s00428-010-1017-2. Epub 2010 Dec 7.
3
GATA3 in development and cancer differentiation: cells GATA have it!发育与癌症分化中的GATA3:细胞拥有GATA!
TRPS1 在原发性和转移性前列腺腺癌、肌层浸润性膀胱尿路上皮癌和乳腺癌中的表达:TRPS1 是否真的对乳腺原发肿瘤具有特异性和敏感性?
Hum Pathol. 2024 Jan;143:42-49. doi: 10.1016/j.humpath.2023.11.012. Epub 2023 Dec 3.
4
RAIDS atlas of significant genetic and protein biomarkers in cervical cancer.宫颈癌重要遗传和蛋白质生物标志物 RAIDS 图谱。
J Gynecol Oncol. 2023 Sep;34(5):e74. doi: 10.3802/jgo.2023.34.e74.
5
A Case of Prostatic Signet-Ring Cell-like Carcinoma with Pagetoid Spread and Intraductal Carcinoma and Long-Term Survival: PD-L1 and Mismatch Repair System Proteins (MMR) Immunohistochemical Evaluation with Systematic Literature Review.1例伴有派杰样播散和导管内癌的前列腺印戒细胞样癌及长期生存:PD-L1和错配修复系统蛋白(MMR)免疫组化评估及系统文献综述
J Pers Med. 2023 Jun 19;13(6):1016. doi: 10.3390/jpm13061016.
6
Immunohistochemical Assays for Bladder Cancer Molecular Subtyping: Optimizing Parsimony and Performance of Lund Taxonomy Classifiers.膀胱癌分子分型的免疫组织化学检测:优化 Lund 分类器的简约性和性能。
J Histochem Cytochem. 2022 May;70(5):357-375. doi: 10.1369/00221554221095530. Epub 2022 Apr 19.
7
Diagnostic Relevance of GATA 3 Expression in Urinary Bladder Carcinoma of Divergent Differentiation and Other Histological Variants.GATA 3表达在分化不同及其他组织学变体的膀胱移行细胞癌中的诊断意义
Indian J Surg Oncol. 2021 Dec;12(4):678-685. doi: 10.1007/s13193-021-01394-6. Epub 2021 Aug 18.
8
The secondary tumor of the prostate derived from upper tract urothelial carcinoma: An autopsy case.源自上尿路尿路上皮癌的前列腺继发性肿瘤:1例尸检病例
IJU Case Rep. 2021 Aug 31;4(6):397-402. doi: 10.1002/iju5.12358. eCollection 2021 Nov.
9
Diagnostic and prognostic implications of a three-antibody molecular subtyping algorithm for non-muscle invasive bladder cancer.三抗体分子分型算法对非肌肉浸润性膀胱癌的诊断和预后意义。
J Pathol Clin Res. 2022 Mar;8(2):143-154. doi: 10.1002/cjp2.245. Epub 2021 Oct 26.
10
Association Between Estrogen Receptors and GATA3 in Bladder Cancer: A Systematic Review and Meta-Analysis of Their Clinicopathological Significance.雌激素受体与 GATA3 在膀胱癌中的相关性:临床病理意义的系统评价和荟萃分析。
Front Endocrinol (Lausanne). 2021 Oct 8;12:684140. doi: 10.3389/fendo.2021.684140. eCollection 2021.
J Cell Physiol. 2010 Jan;222(1):42-9. doi: 10.1002/jcp.21943.
4
Expression of the urothelial differentiation markers GATA3 and placental S100 (S100P) in female genital tract transitional cell proliferations.尿路上皮分化标志物GATA3和胎盘S100(S100P)在女性生殖道移行细胞增殖中的表达。
Am J Surg Pathol. 2009 Mar;33(3):347-53. doi: 10.1097/PAS.0b013e3181908e24.
5
GATA-3 and the regulation of the mammary luminal cell fate.GATA-3与乳腺管腔细胞命运的调控
Curr Opin Cell Biol. 2008 Apr;20(2):164-70. doi: 10.1016/j.ceb.2008.02.003. Epub 2008 Mar 21.
6
Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.尿路上皮蛋白III表达缺失与侵袭性膀胱癌的临床病理特征相关。
Urology. 2008 Aug;72(2):444-9. doi: 10.1016/j.urology.2007.11.128. Epub 2008 Mar 3.
7
Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.高级别前列腺癌与尿路上皮癌的免疫组织化学鉴别
Am J Surg Pathol. 2007 Aug;31(8):1246-55. doi: 10.1097/PAS.0b013e31802f5d33.
8
Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.胎盘S100(S100P)和GATA3:通过互补DNA微阵列发现的移行上皮和尿路上皮癌标志物。
Am J Surg Pathol. 2007 May;31(5):673-80. doi: 10.1097/01.pas.0000213438.01278.5f.
9
Immunohistochemical staining for p63 is useful in the diagnosis of anal squamous cell carcinomas.p63免疫组织化学染色有助于肛管鳞状细胞癌的诊断。
Am J Surg Pathol. 2007 Feb;31(2):285-90. doi: 10.1097/01.pas.0000213362.10756.d3.
10
Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation.Gata-3是乳腺形态发生和管腔细胞分化的重要调节因子。
Nat Cell Biol. 2007 Feb;9(2):201-9. doi: 10.1038/ncb1530. Epub 2006 Dec 24.